CAR-T vs. Bispecific Agents in the Treatment of Refractory Multiple Myeloma

In this video, “CAR-T vs. Bispecific Agents in the Treatment of Refractory Multiple Myeloma”, Sagar Lonial, MD, FACP, and Saad Usmani, MD, MBA, FACP, discuss anti-BCMA treatment strategies.

Targeting of BCMA is proving to be an effective strategy for multiple myeloma (MM). Promising BCMA-directed approaches include CAR T-cells and bispecific T-cell engagers, which have demonstrated impressive efficacy in refractory MM. However, there are advantages and disadvantages for each. Questions of where and how different BCMA-specific therapies may best fit among available options, now and in the future, are discussed.
Previous Article MRD Directed Therapeutic Decision Making in Multiple Myeloma
Next Article Recent Developments and Progress in Chronic Myeloid Leukemia
Print